Clinical trials: Complete Response
Adult Acute Lymphoblastic Leukemia in Remission, Childhood Acute Lymphoblastic Leukemia in Remission
Reduced Intensity Donor Stem Cell Transplant in Treating Patients With High Risk Acute Lymphocytic Leukemia in Complete Remission
The reason for doing this study is to determine whether a new method of blood stem cell transplant (also known as bone marrow transplant) is able to treat acute lymphocytic leukemia.
- Conditions
- Adult Acute Lymphoblastic Leukemia in Remission, Childhood Acute Lymphoblastic Leukemia in Remission, Recurrent Adult Acute Lymphoblastic Leukemia, Recurrent Childhood Acute Lymphoblastic Leukemia
- Trial name
- NCT00031655
- Testing
- nonmyeloablative allogeneic hematopoietic stem cell transplantation, donor lymphocytes, cyclosporine
- Where
- 3 sites in United States
- Volunteers
- 30 people
- Sponsor
- Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium
Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma
Autologous or Donor Stem Cell Transplantation in Treating Patients With Recurrent Non-Hodgkin's Lymphoma (BMT CTN 0202)
This study is designed as a Phase II/III, multi-center trial, comparing two transplant strategies to determine whether non-myeloablative allogeneic Hematopoietic Stem Cell Transplantation (HSCT) will improve long-term…
- Conditions
- Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Grade 3 Follicular Lymphoma, Follicular Lymphoma
- Trial name
- NCT00096460
- Testing
- Cyclophosphamide and Rituximab, Filgrastim, Chemotherapy or Radiation therapy
- Where
- 30 sites in United States
- Volunteers
- 30 people
- Sponsor
- Medical College of Wisconsin
Breast Neoplasms, Breast Cancer
Assessment of Breast Cancer Response to Neoadjuvant Anthracycline-based Chemotherapy by FDG-PET and Molecular Markers
A correlation between early changes in the tumor maximum standardized uptake value (SUVmax) on FDG-PET after one or two cycles of neoadjuvant chemotherapy (NAC) and the pathological response after 6 to 8 cycles has been…
- Trial name
- NCT02600442
- Testing
- non interventional study
- Where
- France
- Volunteers
- 168 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
High-Grade Osteosarcoma
Treatment Patterns and Survival Outcomes in High-Grade Osteosarcoma: A Multicenter Retrospective Study
This is a multicenter, medical-record-based, retrospective observational study of approximately 400 patients with high-grade osteosarcoma treated at four sites in the Republic of Korea.
- Trial name
- NCT07878364
- Where
- 4 sites in South Korea
- Volunteers
- 400 people
- Sponsor
- MedPacto, Inc.
Acute Myeloid Leukemia
Total Marrow and Lymphoid Irradiation Before Donor Transplant and Cyclophosphamide in Treating Patients With Acute Myeloid Leukemia
This pilot phase I trial studies the side effects of total bone marrow and lymphoid irradiation and how well it works with cyclophosphamide in treating patients with acute myeloid leukemia.
- Trial name
- NCT03467386
- Testing
- Allogeneic Hematopoietic Stem Cell Transplantation, Cyclophosphamide, Filgrastim
- Where
- United States
- Volunteers
- 56 people
- Sponsor
- City of Hope Medical Center
Pseudomonas Aeruginosa
Molecular Detection Of Efflux Pump and Virulence Factors Genes in Pseudomonas Aeruginosa
Pseudomonas aeruginosa (PA) is a ubiquitous aerobic, non-fermentative Gram-negative rod that is widely associated with nosocomial pneumonia and can lead to severe illness with poor outcomes, particularly in critically ill people…
- Trial name
- Pseudomonas (NCT05642767)
- Testing
- culture on cetrimide agar, Staining with Gram stain, Antibiotic sensitivity testing
- Where
- Egypt
- Volunteers
- 75 people
- Sponsor
- Sohag University
Bone Sarcoma, Osteosarcoma
Efficacy of Regorafenib Combined With Best Supportive Care as Maintenance Treatment in High Grade Bone Sarcomas Patients
This is a multicenter phase II study concerning patients with high-grade bone sarcoma (HGBS) without complete remission after standard treatment at diagnosis or at relapse.
- Trial name
- REGOMAIN (NCT04698785)
- Testing
- Treatment by regorafenib and best supportive care
- Where
- 16 sites in France
- Volunteers
- 36 people
- Sponsor
- Centre Leon Berard
Gastroenteritis
Evaluation of Immunochromatographic Tests for Campylobacter Detection in Stools
For a long time, culture was the only way to detect Campylobacter. It appears that rapid immunochromatographic tests (ICT) have detected more positive cases compared to culture, ELISA and molecular tests.
- Trial name
- CAMPYTEST (NCT02274922)
- Where
- France
- Volunteers
- 308 people
- Sponsor
- University Hospital, Bordeaux
Acute Lymphoblastic Leukemia, Adult Acute Lymphoblastic Leukemia in Complete Remission
Combination Chemotherapy and Ofatumumab in Treating Patients With Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
This phase II trial studies how well combination chemotherapy and ofatumumab work in treating patients with acute lymphoblastic leukemia or lymphoblastic lymphoma.
- Conditions
- Acute Lymphoblastic Leukemia, Adult Acute Lymphoblastic Leukemia in Complete Remission, Burkitt Leukemia, Burkitt Lymphoma
- Trial name
- NCT01363128
- Testing
- Cyclophosphamide, Cytarabine, Dexamethasone
- Where
- United States
- Volunteers
- 72 people
- Sponsor
- M.D. Anderson Cancer Center
Platelet Transfusion Refractoriness, Acute Leukemia in Remission
Sequential Infusion of CD19 and BCMA CAR-T Cells to Improve PTR in Patients With AL
Alloimmune-mediated platelet transfusion refractoriness(PTR) was usually caused by repeated blood transfusions and pregnancy and accounts for about 20-25% of PTR patients.
- Trial name
- NCT04846439
- Testing
- CAR-T infusion
- Where
- China
- Volunteers
- 20 people
- Sponsor
- The First Affiliated Hospital of Soochow University
Colorectal Cancer
Proposal of a Novel Model for Identifying Complete Response in dMMR Colon Cancer Following Neoadjuvant Immunotherapy
A novel evaluation model for identifying complete response following neoadjuvant immune checkpoint inhibitor therapy therapy in patients with dMMR colon cancer was developed to validated its efficacy in two independent cohorts…
- Trial name
- NCT06980350
- Testing
- PD-1 Inhibitors
- Where
- China
- Volunteers
- 156 people
- Sponsor
- Sun Yat-sen University
Bone Sarcoma, Osteosarcoma
Efficacy and Safety of Regorafenib as Maintenance Therapy After First-line Treatment in Patients With Bone Sarcomas
Randomized, non-comparative, multicentre exploratory phase II study. Two arms concerning patients with bone sarcoma after the first line therapy: in the first arm, patients will be treated with Regorafenib for a maximum of 12…
- Conditions
- Bone Sarcoma, Osteosarcoma, Ewing Sarcoma, Chondrosarcoma
- Trial name
- REGOSTA (NCT04055220)
- Testing
- Treatment by Regorafenib, Surveillance
- Where
- 16 sites in France
- Volunteers
- 168 people
- Sponsor
- Centre Leon Berard
Lymphoma, Non-Hodgkin
Blood Stem Cell Transplant With Low Dose Chemotherapy for Relapsed Follicular Non-Hodgkin's Lymphoma (BMT CTN 0701)
Blood stem cell transplants are one treatment option for people with lymphoma or other types of blood cancers. For this type of treatment, family members or unrelated donors with a similar tissue type usually donate their blood…
- Trial name
- NCT00912223
- Testing
- Hematopoietic Stem Cell Transplant
- Where
- 21 sites in United States
- Volunteers
- 65 people
- Sponsor
- Medical College of Wisconsin
T Cell Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma
Autologous Versus Allogeneic Hematopoietic Stem Cell Transplantation for T-Lymphoblastic Leukemia/Lymphoma in First Complete Remission
To evaluate, through a prospective multicenter observational study, autologous or allogeneic hematopoietic stem cell transplantation (Auto-SCT/allo-SCT)as consolidation therapy in subjects with T lymphoblastic…
- Trial name
- NCT07577531
- Testing
- different stem cell transplantation type
- Volunteers
- 84 people
- Sponsor
- Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Rectal Cancer
Application of Amide Proton Transfer-Weighted Imaging in Predicting Pathological Complete Response After Neoadjuvant Therapy of Rectal Cancer
The goal of this observational study is to learn about the amide proton transfer-weighted imaging for rectal cancer response assessment after neoadjuvant therapy.
- Trial name
- NCT06719414
- Where
- 2 sites in China
- Volunteers
- 320 people
- Sponsor
- Sixth Affiliated Hospital, Sun Yat-sen University
Myelodysplastic Syndromes, Acute Myeloid Leukemia
Oxaliplatin, Fludarabine, and Cytarabine in Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndromes (MDS)
The goal of this clinical research study is to find the highest tolerable dose of oxaliplatin combined with fludarabine plus cytarabine that can be given to patients with Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic…
- Conditions
- Myelodysplastic Syndromes, Acute Myeloid Leukemia, Leukemia
- Trial name
- NCT00480987
- Testing
- Oxaliplatin, Fludarabine, Cytarabine
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- M.D. Anderson Cancer Center
Relapsing/Refractory ALK+ Anaplastic Large Cell Lymphoma
Nivolumab for Pediatric and Adult Relapsing/Refractory ALK+, for Evaluation of Response in Patients With Progressive Disease (Cohort 1) or as Consolidative Immunotherapy in Patients in Complete Remission After Relapse (Cohort 2)
Prospective, non-randomized, single arm phase II trial with 2 cohorts of ALK+ ALCL treated with nivolumab
- Trial name
- NIVO-ALCL (NCT03703050)
- Testing
- Nivolumab cohort 1, Nivolumab cohort 2
- Where
- 13 sites in Denmark, France and 1 more
- Volunteers
- 45 people
- Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
Chronic Hepatitis B
Sustained Viral Response in Patients Achieved HBsAg Level≤100 IU/ml After Completed Interferon Treatment
Chronic hepatitis B (CHB) is a serious liver disease worldwide, and the leading cause of cirrhosis and hepatocellular carcinoma (HCC).
- Trial name
- NCT02348502
- Where
- China
- Volunteers
- 160 people
- Sponsor
- Beijing Ditan Hospital
Meningococcal Infection
Duration of hSBA Response After a Primary Series of Bivalent rLP2086 Followed by a Booster Dose
This study is to assess the longevity of immune response in adolescents for approximately 48 months after receipt of a primary series of bivalent rLP2086 vaccination, which is then followed by a booster dose and an assessment of…
- Trial name
- NCT01543087
- Testing
- blood sampling, bivalent rLP2086
- Where
- 56 sites in United States, Czechia and 4 more
- Volunteers
- 698 people, healthy volunteers welcome
- Sponsor
- Pfizer
Neuroblastoma
Naxitamab and Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) Combined With Isotretinoin for Maintenance Treatment of Patients With High-Risk Neuroblastoma in First Complete Response.
This is a single-arm, multicenter clinical trial conducted in patients ≥ 12 months of age with high-risk neuroblastoma in first complete response.
- Trial name
- NCT06047535
- Testing
- Naxitamab
- Volunteers
- 62 people
- Sponsor
- SciClone Pharmaceuticals